New injection aims to slow vision loss in rare eye disease
NCT ID NCT06292650
First seen Jan 08, 2026 · Last updated May 02, 2026 · Updated 21 times
Summary
This early-stage trial tests the safety of an experimental drug called ZM-02, given as an injection into one eye of 12 people with retinitis pigmentosa, a condition that causes gradual vision loss. The main goal is to check for side effects and monitor eye pressure. The study does not expect to cure the disease, but may help control its progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Beijing Tongren Hospital of Capital Medical University
RECRUITINGBeijing, Beijing Municipality, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.